KROS Keros Therapeutics, Inc.

8-K Current Report

Filed: March 9, 2026

Health Care

Pharmaceutical Preparations

Keros Therapeutics, Inc. (KROS) 8-K current report filed with SEC EDGAR on March 9, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 8.01: Other Events

AI Filing Analysis
8-K

Item 8.01 · Other Events

• Keros partnering with Mass General Hospital to design Phase 2 trial of rinvatercept in ALS patients via HEALEY ALS MyMatch platform
• HEALEY MyMatch is a prestigious adaptive trial platform — entry signals clinical validation and accelerates path to data vs. standalone trial design

+2 more insights

Other Keros Therapeutics, Inc. 8-K Filings

8-K Mar 4, 2026

8-K Feb 26, 2026

Get deeper insights on Keros Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.